a2zJanuary 29, 2021 15
Paroxysmal Choreoathetosis Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.
Paroxysmal choreoathetosis is a disorder characterized by movement disorder occurring due to episodes of involuntary movements in limbs, facial and trunk muscles. This disorder being genetic may occur in several members of a genetically connected family or may occur only in a single member of the family. The gene responsible for the disorder was found to be associated with the epilepsy as well.
Share this article
PANGYO, GYEONGGI PROVINCE, Korea, Jan. 29, 2021 /PRNewswire/
SK Biopharmaceuticals announced that the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-seizure medications (ASMs). The European Commission (EC), which is authorized to approve medicines in the European Union, is expected to issue its decision within approximately 67 days of receipt of the CHMP opinion.
SK Biopharmaceuticals and Arvelle Therapeutics entered into a licensing agreement in 2019 for Arvelle to commercialize SK Biopharmaceuticals cenobamate in Europe. Cenobamate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial-onset (focal-ons
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation.